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Dr. Pan and colleagues in this issue commented that there is
a substantial policy favoring and emphasis on early detection
and treatment of various kinds of cancers prevalent in devel-
oped countries.1 In Taiwan, the government not only provides
Pap smears for cervical cancer screening, but has maintained a
nationwide, free and biennial mammographic screening pro-
gram since 2004.1 There was a significant 10-year delay from
the time that Pap smear screening began to be widely used in
Taiwan in 1995.2,3 Like most medical developments that have
to go through routine channels of administrative review, the
path to ultimate approval by the Taiwanese government can be
challenging. The Pap smear procedure in Taiwan also faced
many difficulties, given that Pap smear was likely first intro-
duced in Taiwan as early as 1974.2,3 Although the benefits of
Pap smear have been long established, more than 20 years
were wasted in the elongated process for this procedure be
accepted as a screening tool. The progress in cancer screening
facilitated by the use of Pap smear has acted to reduce the
substantial onset and spread of invasive cervical cancer in the
majority of women. Since the Pap smear screening program
was introduced, the incidence rate (IR) of invasive cervical
cancer has dramatically decreased and continues to decline.
Because there has been considerably more frequent and earlier
detection of precancer cervical lesions, the IR of invasive
cervical cancer has remained below the IR of pre-cancer
cervical lesion since 1998; that IR remains persistently low
in 2014.2 To date, the covering rate of 3-year Pap smear was
up to 57% of women  30 years of age.2 This covering rate
has helped to decrease the number of newly diagnosed cases of
far-advanced cervical cancer,4 reduce the cost of medical
care,5 and further significantly improved outcomes for patients
and prolonged their lives.
How significant is the mammographic screening program?
It has been reported that the covering rate of the target pop-
ulation in Taiwan (between 45e69 years of age) was nearly
one third in the most recent 2 years,1 contributing to a sub-
stantial increase in the number of cases of breast cancer that
were detected. Therefore, the actual incidence of invasive
breast cancer increased significantly.6 In 2011, the IR of breastcts of interest: The authors declare that there are no conflicts of interest
to the subject matter or materials discussed in this article.
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contributing to a mortality rate of 15.99 per 100,000 women.
This represented the 4th highest mortality rate of all cancer
deaths.6 However, the IR of breast cancer seemed to be con-
tinuously elevated. By contrast, breast cancer-related mortality
also seemed to increase, a trend which appears poised to
remain unchanged in the near future. We do not know whether
or not this increased IR and/or mortality rate of breast cancer
is secondary to Taiwan’s free biennial mammographic
screening program. In fact, this program provided by the
Taiwan’s Health Promotion Administration in the Ministry of
Health and Welfare should be a functional and valuable public
policy to promote women’s health.6 In addition, given the
media attention devoted to the topic of breast cancer, high
profile fundraising events and the abundance of breast cancer
awareness efforts, government officials might concluded that a
majority of women are well informed about breast cancer and
perhaps assume that the path to cancer screening and evalua-
tion is well-marked and free of barriers, as stated by Dr.
Harvey.7 Unfortunately, the mammography screening outcome
appeared to be significantly different and potentially inferior
to that of Pap smear. That is to say, after introducing the
national free mammography screening program, the IR and
mortality rate of breast cancer has increased; by contrast, the
IR and mortality rate of cervical cancer decreased after the
national free Pap smear screening program was introduced.
In addition, the overall quality of the screening mammog-
raphy program seemed to be inferior to that of the Pap smear
screening program. The recall rates of screening mammog-
raphy in Taiwan since 2005 ranged from 9.3% to 10.0%,1
although the result is within the recommended range of the
American College of Radiology. However, just like Dr. Pan
mentioned,1 an unusually high or low recall rate was still
found in Taiwan, suggesting that there are wide variations in
the skill levels of imagers interpreting the results at different
facilities.7
Furthermore, the authors failed to discuss what the next
step of “abnormal mammography screening” will be. This
omission may be a consequence of the lack of consensus
among professional and government-supported organizations
and associated messaging.7 For example, women may expe-
rience extreme anxieties when informed that they should have
a subsequent 6-month follow-up diagnostic test. Some of these
women would likely opt for a breast biopsy, which furtherociation. All rights reserved.
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an elevation of patient emotional embarrassment. By contrast,
the next step of “abnormal Pap smear screening” is well-
established. Most importantly, the emotionally charged issue
of women with “abnormal Pap smear screening” has been
extensively reviewed,4 suggesting that Pap smear as a
screening method is much more acceptable and the cost-
effective than mammography.
Finally, the authors also failed to discuss the following
important issue – the patient burden of screening mammog-
raphy recall. In fact, the subsequent financial charges and
other challenges to patients associated with unnecessary recall
have not been extensively reported in the breast cancer
screening literature.6 In addition, Dr. Pan in this issue might
have displayed a greater interest in the decreasing of false
negative cases instead of false positive screening mammog-
raphy.1 However, false positive screening mammography is an
important issue not only arising from the considerable increase
in financial cost it poses, but also for the emotional cost as
well. It has been reported that the financial burden to patients
from health care utilization due to unnecessary recall follow-
ing a screening mammography was significant and dis-
proportionately distributed.8
Overall, the road to creating an appropriate environment of
cancer screening and diagnosis which can be easily accessed
by and functions well for women in Taiwan remains a long
one. Additionally, the actual value of the screening mam-
mography program in Taiwan is still uncertain, and only time
will tell whether these efforts have a net benefit for women.
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